Citalopram-Induced Hypomania: Clinical Evidence and Guidelines

Incidence and Clinical Evidence

The American Academy of Child and Adolescent Psychiatry (AACAP) guidelines confirm that rare reports of mania/hypomania have occurred with SSRIs as a class, including citalopram, with a recognized adverse effect documented in clinical guidelines 1, 2

Behavioral activation typically occurs early in treatment, presents as motor/mental restlessness, insomnia, impulsiveness, talkativeness, disinhibited behavior, or aggression, and usually improves quickly after SSRI dose reduction or discontinuation, as noted by the AACAP guidelines 1, 2
True mania/hypomania may appear later in treatment, persists despite dose reduction, and requires more active pharmacological intervention, such as mood stabilizers or antipsychotics, according to the AACAP guidelines 1, 2

The AACAP guidelines for bipolar disorder specifically note that antidepressants, including SSRIs, may destabilize mood or incite manic episodes in bipolar patients, and should only be used as adjuncts when patients are already taking at least one mood stabilizer 3, 4
Treatment with SSRIs should be avoided entirely in patients with bipolar disorder history unless adequately covered by mood stabilizers, as recommended by clinical evidence 5

Close monitoring is essential, especially in younger children, who have higher rates of behavioral activation, as recommended by the AACAP guidelines 1
If hypomania develops, discontinuation of citalopram and consideration of mood stabilizer treatment is necessary, according to the AACAP guidelines 1, 2, 3, 4

The AACAP recommendation for slow up-titration and close monitoring, particularly starting with subtherapeutic "test" doses, is supported by case reports with escitalopram, which suggest a dose-related pattern of manic/hypomanic symptoms 1, 6

The American Academy of Child and Adolescent Psychiatry suggests that unmasking of underlying bipolar disorder should be considered, particularly given history of depression and intense anger, in patients with antidepressant-induced hypomania 7
The Annals of Internal Medicine recommends continuing mood stabilizer or atypical antipsychotic for 4-9 months minimum after symptom resolution, to prevent relapse of hypomanic symptoms 8

The Journal of the American Academy of Child and Adolescent Psychiatry warns that antidepressants may unmask underlying bipolar disorder, and should be used with caution in patients with mood instability 7

The Annals of Internal Medicine suggests monitoring daily for worsening symptoms, including agitation, irritability, and suicidality, especially during the first 1-2 weeks after medication changes 8